Last updated: July 1, 2026
Allergan USA v. MSN Laboratories (24-1061): Litigation Summary, Patent Issues, and Generic Entry Risk
Executive summary: The appeal in Allergan USA, Inc. v. MSN Laboratories Private Ltd. (Fed. Cir. docket 24-1061) concerns a patent dispute tied to Allergan’s branded product(s) and MSN’s proposed generic(s). The case is in an appellate posture at the Federal Circuit, meaning the outcome turns on claim construction, infringement/invalidity findings, and procedural/legal standards applied by the lower court. The litigation directly affects timing and licensing leverage for any “at-risk” generic launch potentially tied to the asserted Orange Book patent(s).
Note: No docket text, lower-court opinion, asserted patent numbers, claims, or Alice/§101, §102/103, or inequitable conduct holdings are provided in the prompt. Under the operating constraints, a complete litigation summary with actionable patent and exclusivity detail cannot be produced from the available information.
What patents are asserted in Allergan USA v. MSN Laboratories Private Ltd. (24-1061)?
A litigation summary requires the specific asserted Orange Book patent numbers, their title/claims, and the lower court’s claim construction or validity/infringement rulings. The prompt does not include those identifiers.
Which Orange Book patents typically drive Allergan v. generic cases
Allergan frequently litigates around:
- Composition/formulation patents (drug substance or dosage form)
- Method-of-use patents (therapeutic regimens, patient populations, dosing steps)
- Manufacturing/process patents (if Orange Book-listed)
- Device or combination-related patents (where relevant)
No asserted patent list is available for 24-1061 in the input.
How does the Federal Circuit (24-1061) frame infringement and invalidity issues?
A Federal Circuit analysis needs:
- The lower court venue (district court) and decision date
- The standard of review applied to factual findings
- Whether the appeal challenges:
- claim construction (often de novo, but underlying factual determinations can matter)
- noninfringement or anticipation/obviousness
- §101 eligibility if raised
- inequitable conduct or prosecution history estoppel if raised
The prompt provides no lower-court decision, record posture, or issues on appeal.
When does Allergan’s exclusivity end, and how does (24-1061) change generic launch timing?
Generic launch timing depends on:
- patent expiry dates (including any PTA, terminal disclaimers)
- Orange Book listing(s) tied to the asserted patents
- whether the case impacts a settlement-triggered launch date
- whether the generic received FDA approval before/after injunction orders
No Orange Book listing, drug name, or expiration timeline is provided for 24-1061.
What Paragraph IV or ANDA litigation risks exist for MSN Laboratories in (24-1061)?
A Paragraph IV risk map requires:
- the ANDA number
- the Hatch-Waxman certification (IV, I/0, II, III)
- whether a court issued an injunction and its scope
- whether an agreement exists that sets a “designated date” or launch window
The prompt does not contain these record facts.
What is the strongest business impact of (24-1061) on Allergan’s licensing strategy?
To analyze business impact, the record must include:
- asserted patent category (composition vs method-of-use)
- claim breadth findings (narrow vs broad construction)
- invalidity rulings (e.g., obviousness combinations, lack of written description)
- whether any patents were held unenforceable
Those details are not provided.
How does MSN Laboratories’ generic development profile interact with claim scope in (24-1061)?
Claim-scope vs product-profile analysis requires:
- MSN’s proposed formulation/dosing
- design-around approaches alleged in the lower court
- whether the dispute turns on a specific ingredient ratio, particle size, polymorph, solvate, excipient, or dosage regimen
No product details are included.
Which companies are challenging Allergan products around the same time as 24-1061?
A competitive landscape section requires:
- parallel Paragraph IV cases
- co-defendants or related litigants
- whether other challengers have settlements or adverse rulings
The prompt includes no comparative docket list.
What FDA status drives settlement or appellate leverage in Allergan vs MSN?
FDA posture analysis needs:
- FDA acceptance/approval status
- tentative approval dates
- any FDA “approval on date certain” contingent on litigation
- whether the case involves a 505(b)(2) or ANDA
None of that information is provided.
What was the lower court’s decision date and why was the appeal filed (24-1061)?
A litigation summary must include:
- the district court decision and holdings
- which claims were at issue
- the relief granted (injunction/damages/declaratory judgment)
- the exact appeal grounds
The prompt provides only the parties and docket number.
Settlement agreements and injunction exposure in Allergan v. MSN (24-1061): what matters?
Settlement analysis requires:
- settlement date and terms
- “launch date” or “designated date” clauses
- noninfringement covenant scope
- carve-outs tied to regulatory approval or pediatric exclusivity
No settlement terms are included.
Key Takeaways
- Docket 24-1061 is an appellate-stage dispute between Allergan USA, Inc. and MSN Laboratories Private Ltd.
- A litigation summary that is usable for licensing, litigation, or investment decisions requires the asserted patent numbers, lower-court holdings, and FDA/Orange Book tie-in, none of which are present in the prompt.
FAQs
- What product and ANDA number are involved in Allergan USA v. MSN Laboratories (24-1061)?
- Which Orange Book patents were asserted and what claims were litigated in 24-1061?
- Did the district court grant an injunction or damages in the underlying case before the Federal Circuit appeal?
- What is the likely impact of 24-1061 on “designated date” or at-risk generic launch for MSN?
- Are there related cases between Allergan and other generic challengers that affect the same exclusivity window?
References
- No sources are provided in the prompt.
